LOCUS       sequence-95777-e        1031 bp    DNA     linear   UNA 15-DEC-2025
DEFINITION  Expressed murine IFITM3-C71,72A with an N-terminal HA tag in 
            mammalian cells.
ACCESSION   .
VERSION     .
KEYWORDS    .
SOURCE      natural DNA sequence
  ORGANISM  unspecified
REFERENCE   1  (bases 1 to 1031)
  AUTHORS   Yount JS, Moltedo B, Yang YY, Charron G, Moran TM, Lopez CB, Hang HC
  TITLE     Palmitoylome profiling reveals S-palmitoylation-dependent antiviral 
            activity of IFITM3.
  JOURNAL   Nat Chem Biol. 2010 Aug;6(8):610-4. doi: 10.1038/nchembio.405. Epub 
            2010 Jul 4.
  PUBMED    20601941
REFERENCE   2  (bases 1 to 1031)
  AUTHORS   .
  TITLE     Direct Submission
  JOURNAL   Exported Dec 15, 2025 from SnapGene Server 8.0.1
            https://www.snapgene.com
COMMENT     SGRef: number: 1; type: "Journal Article"; doi: 
            "10.1038/nchembio.405"; journalName: "Nat Chem Biol"; date: 
            "2010-08"; volume: "6"; issue: "8"; pages: "610-4"
COMMENT     Sequence Label: pCMV-HA-mIFITM3-C71,72A
FEATURES             Location/Qualifiers
     source          1..1031
                     /mol_type="genomic DNA"
                     /organism="unspecified"
     CDS             complement(488..514)
                     /codon_start=1
                     /product="HA (human influenza hemagglutinin) epitope tag"
                     /label=HA
                     /translation="YPYDVPDYA"
     intron          578..674
                     /label=SV40 intron
                     /note="modified SV40 intron with splice donor and acceptor 
                     sites"
     primer_bind     complement(791..815)
                     /label=LNCX
                     /note="Human CMV promoter, forward primer"
     promoter        complement(812..1015)
                     /label=CMV promoter
                     /note="human cytomegalovirus (CMV) immediate early 
                     promoter"
     primer_bind     complement(841..861)
                     /label=CMV-F
                     /note="Human CMV immediate early promoter, forward primer"
ORIGIN
        1 tgtctggatc cccgcggccg cggtacctcg agagatctcg gtcgacttaa gtgtgaaggt
       61 tttgagcgtt aagaacaatg atgatgacac taacaatggt gataacaacc atcaggatgc
      121 tgaggaccaa ggtgctgatg ttcaggcact tagcagtgga ggcgtaggcc tgggctccag
      181 tcacatcacc caccatcttc cgatccctag acttcacgga gtaggcatag gctatgaagc
      241 ccagtgctgc gaagttcatg aagagtgtat tgaacaggga ccagaccaca tggtcaggca
      301 ccgacacctc tctgggcatg ttgatcacag tagttctgac agaagccgat ccgtgcggtg
      361 cccccatctc agccacctca tattcttcct tgattctttc gtagtttggg ggctgtcctc
      421 cactggcagc ggtgatgaag gcttgagaag tgtggttcat gggaattcgg gcctccatgg
      481 ccataagagc gtaatctgga acatcgtatg ggtacatggt gggcccgcgg gtacaattcc
      541 gcagctttta gagcagaagt aacacttccg tacaggccta gaagtaaagg caacatccac
      601 tgaggagcag ttctttgatt tgcaccacca ccggatccgg gacctgaaat aaaagacaaa
      661 aagactaaac ttaccagtta actttctggt ttttcagttc ctctagtacc ggatcctcta
      721 gagtccggag gctggatcgg tcccggtgtc ttctatggag gtcaaaacag cgtggatggc
      781 gtctccaggc gatctgacgg ttcactaaac gagctctgct tatatagacc tcccaccgta
      841 cacgcctacc gcccatttgc gtcaatgggg cggagttgtt acgacatttt ggaaagtccc
      901 gttgattttg gtgccaaaac aaactcccat tgacgtcaat ggggtggaga cttggaaatc
      961 cccgtgagtc aaaccgctat ccacgcccat tgatgtactg ccaaaaccgc atcaccatgg
     1021 taatagcgat g
//
